Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples